Targeted Nanoparticles for Glioblastoma Brain Tumors
Official title: Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
Funded at Nanovalent Pharmaceuticals, INC. · NIH-11145974 · Data updated 2026-11-12
This project is developing tiny, targeted particles to deliver medicine directly to brain tumor cells, aiming to help people with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanovalent Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Bozeman, United States) |
| Project start | August 8, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R42CA281707-03 |
| Project ID | NIH-11145974 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is focused on adults with glioblastoma multiforme (GBM) and other intractable brain tumors.
✕Less likely to help
Patients with non-brain tumors or those whose tumors do not express the specific antigens targeted by these nanoparticles may not benefit from this particular treatment.
What this research studies
Glioblastoma (GBM) is a very aggressive brain tumor that is difficult to treat because most medicines cannot cross the protective blood-brain barrier. This project is creating special nanoparticles designed to overcome this barrier and specifically target human brain tumor cells. Once inside the tumor cells, these nanoparticles release powerful anti-cancer drugs, working to kill the cancer cells and potentially shrink the tumor. The ultimate goal is to find a new way to treat these challenging brain tumors and improve patient outcomes.
Why it matters
Potential benefit: If successful, this approach could offer a new way to treat aggressive brain tumors like glioblastoma, potentially extending survival and improving outcomes.
How similar studies have gone: This approach uses a novel method to overcome the blood-brain barrier, a challenge that has limited the success of traditional cancer treatments for brain tumors.
Where this research is happening
-
Nanovalent Pharmaceuticals, INC.
Bozeman, United States Active
Researchers
- Principal investigator: Nagy, Jon Owen — Nanovalent Pharmaceuticals, INC.
- Study coordinator: Nagy, Jon Owen
Related research
Other NIH-funded projects on the same topics.
-
Targeting brain tumors with nanoparticles for treatment
This study is testing a new kind of tiny particle that can deliver cancer-fighting drugs right to brain tumors, hoping to shrink the tumors and help people with glioblastoma live longer and healthier lives.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.